Jefferies Financial Group Reiterates “Hold” Rating for Marinus Pharmaceuticals (NASDAQ:MRNS)

Marinus Pharmaceuticals (NASDAQ:MRNS)‘s stock had its “hold” rating reaffirmed by equities research analysts at Jefferies Financial Group in a research report issued on Friday, Benzinga reports. They currently have a $0.50 price target on the biopharmaceutical company’s stock, down from their prior price target of $5.00. Jefferies Financial Group’s price target would indicate a potential upside of 23.43% from the stock’s current price.

Other equities analysts have also recently issued research reports about the company. JMP Securities reiterated a “market perform” rating on shares of Marinus Pharmaceuticals in a report on Thursday. EF Hutton Acquisition Co. I upgraded shares of Marinus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, September 30th. HC Wainwright reissued a “buy” rating and issued a $11.00 target price on shares of Marinus Pharmaceuticals in a research note on Wednesday, August 14th. StockNews.com raised shares of Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, October 4th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $13.00 price objective on shares of Marinus Pharmaceuticals in a research report on Tuesday, September 24th. Eight equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $6.07.

Marinus Pharmaceuticals Stock Performance

Shares of MRNS opened at $0.41 on Friday. Marinus Pharmaceuticals has a fifty-two week low of $0.26 and a fifty-two week high of $11.26. The company’s fifty day moving average is $1.54 and its 200 day moving average is $1.61. The stock has a market capitalization of $22.31 million, a PE ratio of -0.15 and a beta of 1.14.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.01). Marinus Pharmaceuticals had a negative net margin of 493.14% and a negative return on equity of 7,831.35%. The business had revenue of $8.06 million for the quarter, compared to analysts’ expectations of $9.05 million. During the same quarter in the prior year, the company posted ($0.61) earnings per share. As a group, research analysts forecast that Marinus Pharmaceuticals will post -1.93 earnings per share for the current year.

Institutional Investors Weigh In On Marinus Pharmaceuticals

Several large investors have recently added to or reduced their stakes in MRNS. Renaissance Technologies LLC bought a new stake in shares of Marinus Pharmaceuticals during the second quarter valued at approximately $727,000. Wellington Management Group LLP increased its holdings in Marinus Pharmaceuticals by 54.8% during the 4th quarter. Wellington Management Group LLP now owns 241,299 shares of the biopharmaceutical company’s stock worth $2,623,000 after purchasing an additional 85,455 shares during the period. Vanguard Group Inc. raised its position in Marinus Pharmaceuticals by 5.0% during the 1st quarter. Vanguard Group Inc. now owns 2,805,920 shares of the biopharmaceutical company’s stock valued at $25,366,000 after purchasing an additional 132,689 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in shares of Marinus Pharmaceuticals in the 2nd quarter worth $813,000. Finally, Hussman Strategic Advisors Inc. grew its position in shares of Marinus Pharmaceuticals by 14.3% during the 2nd quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock worth $98,000 after buying an additional 10,500 shares in the last quarter. 98.80% of the stock is owned by hedge funds and other institutional investors.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.